AUM Biosciences

AUM Biosciences is a Singapore-headquartered clinical-stage biotechnology company focused on developing precision oncology therapeutics. Its approach centers on deploying multi-faceted inhibition strategies to overcome cancer resistance, with a particular emphasis on addressing cancers prevalent in the Asia-Pacific region. The company’s pipeline includes candidates such as AUM001, a selective MNK inhibitor that impairs oncogenic protein translation, which is currently undergoing clinical trials in combination with immunotherapy for indications including colorectal, non-small cell lung, and urothelial cancers. By integrating innovative clinical trial designs and prioritizing cost-effective development, AUM Biosciences seeks to accelerate the delivery of impactful treatments to global markets while addressing significant unmet medical needs in oncology.

The company aims to democratize cancer management by pioneering an Asia-to-global strategy that challenges traditional drug development models. This framework focuses on leveraging regional research efficiencies and clinical expertise to create accessible and affordable therapies, ensuring that advancements meet rigorous global standards. By targeting specific oncogenic mechanisms to reverse drug resistance, AUM Biosciences works to improve patient outcomes and streamline the development path for early-stage assets. Through its leadership, which includes experienced clinicians and medical researchers, the company engages in strategic partnerships and clinical development to bridge the gap between regional healthcare needs and global therapeutic innovation.